AZ's Zook adds MedImmune to his responsibilities
AstraZeneca's chief marketer Tony Zook is stepping in as interim head of MedImmune following the announcement that Dave Mott, president and chief executive of the biologics unit, will step down at the end of July.
Zook will continue to serve as CEO of AstraZeneca's North American business and EVP of global marketing while dividing his time between AstraZeneca's Wilmington, DE, HQ and MedImmune in Gaithersburg, MD.
“He'll be leaning on his leadership team here to continue driving the business,” said an AstraZeneca spokesperson.
The company would not disclose its timeframe for the search but said a process was in place for finding a permanent chief for MedImmune, which AstraZeneca acquired a year ago. MedImmune has since absorbed another AstraZeneca acquisition, Cambridge Antibody Technology, and the firm's other biologics operations, and has submitted a biologics license application for investigational monoclonal antibody motavizumab.